KKR to Acquire Integer for $5.7 Billion

Integer Holdings Corporation (ITGR) entered a merger agreement on August 3, 2026, to be acquired by KKR & Co. Inc. (KKR) in a deal valued at $5.7 billion.

Deal Structure:

Integer stockholders will receive $127 per share in cash, representing a premium of 4.78% from the stock’s last close.

Company Profile:

Integer is a medical device contract development and manufacturing organization (CDMO) that designs and manufactures components and finished devices for medical device companies. The company primarily serves the cardiovascular, neuromodulation, vascular, orthopedic, and advanced surgical markets through its global manufacturing network.

KKR is a global investment firm that manages alternative assets across private equity, credit, real assets, and infrastructure. The company also provides capital markets and insurance solutions through its investment funds and insurance subsidiaries.

Deal Details and Timeline:

Last year, WSJ reported that activist investor Irenic Capital Management had built a stake of more than 3% in Integer and was urging the medical-device outsourcing company to refresh its board and consider a sale. The stock was trading at $74.13 when Irenic said that Integer could be more attractive as a private company.

The transaction is expected to close by the end of 2026.

KKR will finance the acquisition through a combination of equity from investment funds managed by KKR and committed debt financing.

Integer was advised by Goldman Sachs on financial matters and by Davis Polk & Wardwell on legal matters. KKR was advised by Centerview Partners, Barclays, Citi, and Raymond James on financial matters, and by Kirkland & Ellis on legal matters.

KKR is buying Integer at 15.13 times its EBITDA.

Deal Metrics:

For further insights into the intricacies of this M&A deal, please refer to the Deal Metrics page here:

Deal Metrics for the acquisition of Integer Holdings Corporation (ITGR) by KKR & Co. Inc. (KKR)

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart of the merger from announcement through eventual completion or failure.
• Events as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
• News and SEC filings.
• A history of deal updates.
• And much more.

Disclaimer: Please ensure to conduct your own comprehensive research before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article